Through CDR grafting, AlphaFold2-based homology modeling, MD simulations, and molecular docking, the nanobody was shown to have favorable physicochemical properties, low immunogenicity, and strong potential to block the PD-1/PD-L1 and PD-1/PD-L2 interactions, a critical pathway in cancer immunotherapy. This evidence concerns the gene PDCD1 and cancer.